Zipeprol

Zipeprol
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • CA: Schedule III
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • US: Schedule I
  • Schedule II international
Identifiers
IUPAC name
  • 1-methoxy- 3-[4-(2-methoxy- 2-phenylethyl)piperazin- 1-yl]- 1-phenylpropan- 2-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.047.432
Edit this at Wikidata
Chemical and physical data
FormulaC23H32N2O3
Molar mass384.520 g·mol−1
3D model (JSmol)
SMILES
  • OC(CN1CCN(CC1)CC(OC)c2ccccc2)C(OC)c3ccccc3
InChI
  • InChI=1S/C23H32N2O3/c1-27-22(19-9-5-3-6-10-19)18-25-15-13-24(14-16-25)17-21(26)23(28-2)20-11-7-4-8-12-20/h3-12,21-23,26H,13-18H2,1-2H3 checkY
  • Key:VSTNNAYSCJQCQI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Zipeprol is a centrally acting cough suppressant developed in France in the 1970s.[1] It is not a morphinan derivative (in contrast to codeine and dextromethorphan). Zipeprol acts as a local anaesthetic and has mucolytic, antihistamine and anticholinergic properties.[2] It is sold with several brand names such as Zinolta and Respilene. It is not available in the United States or Canada and has been discontinued in Europe. It is still available in some countries in Asia and South America.

Zipeprol has been misused in Korea, mainly for the hallucinations it produces. Such use has become an issue due to the seizures and various neurological side effects it causes at high dosages.[3]

References

  1. Patent US 3718650, Mauvernay RY, "New Derivatives of Substituted Piperazines", issued 1973-02-27
  2. Rispat G, Burgi H, Cosnier D, Duchêne-Marullaz P, Streichenberger G (April 1976). "General pharmacological properties of a new non-opiate antitussive: zipeprol (3024 CERM). I. Action on respiratory function and acute toxicity". Arzneimittel-Forschung. 26 (4): 523–30. PMID 8057.
  3. Chung H, Park M, Hahn E, Choi H, Choi H, Lim M (October 2004). "Recent trends of drug abuse and drug-associated deaths in Korea". Annals of the New York Academy of Sciences. 1025 (1): 458–64. Bibcode:2004NYASA1025..458C. doi:10.1196/annals.1316.056. PMID 15542749.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.